| Name | Title | Contact Details |
|---|
Biota Pharmaceuticals is focused on the discovery and development of direct-acting antivirals to treat infections that affect a significant number of patients globally. The Company has four product candidates in development that address viral infections that have limited therapeutic options. We are currently enrolling patients for the Phase 2b SPIRITUS trial for vapendavir, a potent, broad spectrum capsid inhibitor of enteroviruses, for the treatment of human rhinovirus (HRV) infected patients with moderate-to-severe asthma. Our second Phase 2 clinical product candidate is BTA074 (AP611074), a novel topical treatment for genital warts caused by HPV types 6 and 11. We also are developing BTA-C585, an oral fusion inhibitor in development for the treatment of respiratory syncytial virus infections. We anticipate beginning a Phase 1 clinical trial with BTA-C585 in Q3 2105. Laninamivir octanoate, a one-time, inhaled neuraminidase for the treatment of influenza A and B infections has completed a global Phase 2 trial.
Matinas BioPharma is a clinical-stage biopharmaceutical company focused on development of its lead product candidate, MAT9001, for the treatment of cardiovascular and metabolic conditions. MAT9001 is a prescription-only omega-3 fatty acid-based composition, comprised primarily of EPA and DPA, under development for hypertriglyceridemia, that was specifically designed to overcome the shortcomings seen from other agents in the omega-3 class. Company leadership has a deep history and knowledge of cardiovascular drug development and is supported by a world-class team of scientific advisors. The company will soon begin enrolling MAT9001 in a confirmatory head-to-head PK/PD study vs Vascepa, after having shown superiority versus Vascepa® (icosapent ethyl) in reducing serum triglycerides, Total- and Non-HDL-Cholesterol, apolipoprotein CIII and PCSK9 levels in a previous study, with data expected in Q42020. In addition, the Company is developing MAT2203, an oral, encochleated formulation of Amphotericin B, to treat serious invasive fungal infections. The drug is based on Matinas` proprietary lipid nano-crystal (“LNC”) platform technology which can help solve complex challenges relating to the safe and effective delivery of potent medicines, potentially making them more targeted, less toxic and orally bioavailable.
We are pleased to offer clinicians the first of many advances, the GI-MAP™. The GI-MAP™ (GI-Microbial Assay Plus) stool test utilizes cutting edge, FDA-approved technology to provide a true DNA/PCR based stool analysis which provides actionable informa...
The world leader in addiction treatment with over 20 years of experience and a patient-focused approach. We didn`t become the world leader in addiction treatment overnight. Our endeavor started small, with one singular focus – to intimately understand the journey of individuals suffering with addiction. People with addiction are often stereotyped and discounted, creating an environment where many are under-diagnosed, undertreated and under-supported. They`re often unaware of their treatment options, have limited access to treatment, or simply don`t seek it out because they`re afraid of being stigmatized. Since our inception, we have actively partnered with healthcare professionals, the public health community, policy makers, and payers to humanize people suffering from addiction and to treat addiction as a chronic, relapsing medical condition rather than a social disorder. We believe that people with addiction should be treated as patients, just like people with other chronic diseases. The past two decades have been marked by strong growth and an expansion into more than 40 countries. While treatment for opioid use disorder has seen much innovation, we at Indivior are building on our intimate understanding of the patient journey to further advance addiction treatment including opiate overdose, alcohol use disorders, and co-occurring conditions such as schizophrenia by bringing to market novel treatment solutions worldwide. We at Indivior are on an endeavor – one that is focused on individual patients around the world. Our name reflects this as the key words individual and endeavor harmoniously blend together. It represents and empathizes with the often difficult journey each individual patient takes to overcome the challenges of addiction – a chronic relapsing disease. The patient continues to drive our decisions. Our guiding principles foster a corporate culture of trust, innovation, and a pioneering spirit. We work with the urgency and zeal required to achieve our vision that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of addiction.
BrainScope is a Bethesda, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.